维生素MK-7对骨量减少绝经后女性骨密度和微结构的影响:一项为期3年的随机安慰剂对照临床试验
该随机、安慰剂对照、双盲临床试验纳入142例骨量减少的绝经后女性,每日给予维生素K2(375 μg MK-7)或安慰剂,两组均补充维生素D3(38 μg/天)和钙(800 mg/天),持续3年。结果显示,MK-7组未羧化骨钙素在1年后较安慰剂组显著降低(-65.2 ± 23.5% vs -0.03 ± 38.5%,p < 0.01),但3年后两组骨密度、骨转换标志物及骨微结构变化均无差异。
要点
- MK-7 375 μg/天补充3年未改善骨量减少绝经后女性的骨密度。
- MK-7组1年后未羧化骨钙素较安慰剂组显著降低,但3年后骨转换标志物组间无差异。
- 3年后HRpQCT和DXA骨小梁评分评估的骨微结构变化两组相似。
核心结论
- 每日375 μg MK-7作为钙和维生素D补充的附加治疗增加了骨钙素的羧化,但治疗3年未影响骨转换生化标志物、骨密度或骨微结构。
研究设计与样本
- 随机、安慰剂对照、双盲临床试验,纳入142例骨量减少的绝经后女性,每日接受维生素K2(375 μg MK-7)或安慰剂,持续3年;两组均接受维生素D3(38 μg/天)和钙(800 mg/天)。
主要发现
- 1年后未羧化骨钙素在MK-7组降低-65.2 ± 23.5%(均值±标准差),安慰剂组降低-0.03 ± 38.5%,p < 0.01。
- 3年后全髋aBMD在MK-7组降低1.5 ± 2.5%、安慰剂组降低2.4 ± 2.7%;股骨颈aBMD在MK-7组降低1.5 ± 3.5%、安慰剂组降低1.0 ± 5.0%;腰椎aBMD在MK-7组降低1.8 ± 3.9%、安慰剂组降低1.1 ± 3.1%;组间差异均无统计学意义(p > 0.09)。
- 3年后两组骨转换标志物变化相似。
- 3年后HRpQCT和DXA骨小梁评分评估的骨微结构变化两组相似;作者此前曾报告1年后MK-7组骨微结构改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We conducted a randomized placebo-controlled double-blinded clinical trial of MK-7 or placebo daily for 3 years in postmenopausal women with osteopenia. BMD decreased at all sites without differences between the MK-7 and placebo-treated women. Changes in bone turnover markers and microstructure were similar between the two groups. INTRODUCTION: Vitamin K is a cofactor in the carboxylation of osteocalcin (OC) and carboxylated OC promotes mineralization of bone. Clinical studies suggest that vitamin K2 prevents bone loss. The aim of the study was to investigate the effect of vitamin K2 as an add-on to calcium and vitamin D supplementation on osteocalcin, bone mass, and microarchitecture in postmenopausal women. METHODS: We conducted a randomized placebo-controlled double-blinded clinical trial, including 142 postmenopausal women with osteopenia who received vitamin K2 (375 μg MK-7) or placebo daily for 3 years. Both groups received vitamin D3 (38 μg/day) and calcium (800 mg/day). We measured bone turnover markers in serum and bone mineral density and microarchitecture by DXA and HRpQCT. RESULTS: Undercarboxylated osteocalcin decreased in the MK-7-group (- 65.2 ± 23.5%) (mean ± SD) compared with the placebo group (- 0.03 ± 38.5%), p < 0.01 after 1 year. After 3 years, aBMD decreased at all sites without differences between the MK-7 and placebo-treated women (p > 0.09). aBMD decreased at the total hip by 1.5 ± 2.5% and 2.4 ± 2.7% in the MK-7 and the placebo groups, respectively, at the femoral neck by 1.5 ± 3.5% and 1.0 ± 5.0% in the MK-7 and the placebo groups, respectively, and at the lumbar spine by 1.8 ± 3.9% and 1.1 ± 3.1% in the MK-7 and the placebo groups, respectively. Changes in bone turnover markers were also similar between the two groups.We have previously reported improved microarchitecture with MK-7 after 1 year. However, changes in microstructure over 3 years were similar between the two groups, as assessed by both HRpQCT and DXA trabecular bone score. CONCLUSION: Treatment with MK-7 375 μg daily as an add-on to calcium and vitamin D increased carboxylation of osteocalcin. However, treatment of postmenopausal women with osteopenia for 3 years did not affect biochemical markers of bone turnover, bone mineral density, or bone microarchitecture. TRIAL REGISTRATION: The study was registered at Clinicaltrial.gov : NCT01922804 .
引用
- Rønn SH, Harsløf T, Oei L, et al. The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial. Osteoporos Int. 2020. PMID: 33030563. doi:10.1007/s00198-020-05638-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。